Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
BEIGENE NZ UNLIMITED,Zanubrutinib,"CLL or SLL , relapsed or refractory, second line",Zanubrutinib (BRUKINSA),Options for investment,Community and Hospital,Oncology Agents and Immunosuppressants
